Amring Pharmaceuticals Inc. Announces the Approval and Launch of Generic Isoproterenol Hydrochloride Injection USP

On Aug 5, 2021

Amring Pharmaceuticals Inc. (Amring), a niche generic and brand pharmaceutical company, announced that it has received FDA approval for generic Isoproterenol Hydrochloride USP, (0.2 mg/mL) available as 1 mL or 5 mL Single-Dose Vials, (AP rated generic equivalent of Isuprel), and has immediately begun commercialization activity.

Isoproterenol Hydrochloride Injection USP is indicated for:

mild or transient episodes of heart block that do not require electric shock or pacemaker therapy;
for serious episodes of heart block and Adams-Stokes attacks (except when caused by ventricular tachycardia or fibrillation);
for use in cardiac arrest until electric shock or pacemaker therapy, the treatments of choice, is available;
for bronchospasm occurring during anesthesia; and
as an adjunct to fluid and electrolyte replacement therapy and the use of other drugs and procedures in the treatment of hypovolemic and septic shock, low cardiac output (hypoperfusion) states, congestive heart failure, and cardiogenic shock.

“We are pleased to add Isoproterenol Hydrochloride Injection USP to our generics portfolio, this product brings long term value to patients and customers in our target markets,” stated Daniel Carbery, President and CEO of Amring. “We look forward to realizing the benefits of this, and other product launches and future business development activities in 2021.”